Functional neurological disorder (FND) imposes a substantial economic burden on individuals, families, and health systems, even though it does not always receive the same attention as other chronic neurological conditions. The disorder often presents with symptoms such as non-epileptic seizures, weakness, movement disorders, and sensory changes, which can lead to frequent encounters with emergency and acute care services. These recurrent emergency visits, repeated diagnostic assessments, and prolonged periods of disability together create a complex pattern of direct and indirect cost that affects multiple layers of society.
One of the most significant contributors to the economic burden is the high rate of misdiagnosis and diagnostic delay. Many people with FND initially undergo extensive investigations to rule out structural neurological diseases such as epilepsy, stroke, or multiple sclerosis. This process can involve neuroimaging, repeated electroencephalograms, extensive laboratory testing, and specialist consultations. Each additional test and specialist referral adds incremental cost, and when the diagnosis remains unclear, patients may return repeatedly to acute care settings, compounding healthcare utilization without improving outcomes.
The pattern of care for FND is often fragmented, involving neurologists, psychiatrists, psychologists, physiotherapists, primary care providers, and sometimes pain or rehabilitation specialists. Lack of coordinated, multidisciplinary pathways increases the likelihood of overlapping or duplicated services. In the absence of a clear treatment plan, patients may cycle through multiple providers and treatment trials, some of which offer limited clinical benefit but carry considerable cost. From the health system perspective, this amounts to a sizable hidden expenditure embedded across neurology, psychiatry, emergency medicine, and primary care budgets.
Frequent hospitalizations further amplify the financial strain. Individuals with FND, especially those with seizure-like episodes or motor symptoms, are often admitted for observation, diagnostic workup, or management of acute episodes. These admissions can be lengthy, particularly when there is uncertainty about the diagnosis or when recurrent episodes occur during the hospital stay. Inpatient care is among the most expensive components of modern healthcare, so even a relatively small cohort of patients with repeated admissions can exert a disproportionate impact on overall neurological care costs.
Another layer of economic burden arises from the chronicity of symptoms in many patients. While some individuals experience transient episodes, a substantial proportion develop long-standing or fluctuating disability. This can require ongoing outpatient follow-up, maintenance therapies, and periodic reassessment, embedding long-term cost into both specialized and primary care. When appropriate psychological and rehabilitative services are unavailable or underfunded, the burden shifts toward recurrent acute care encounters, which are generally less efficient and more expensive for managing a chronic condition.
The financial consequences for patients and families are also considerable. FND often affects people in their prime working years, and persistent symptoms can lead to partial or complete loss of employment. Reduced earnings, increased informal caregiving demands, and out-of-pocket expenses for travel, therapy, or private consultations all contribute to financial strain. For households with limited savings or precarious employment, the combination of lost income and ongoing medical costs can be destabilizing, increasing the risk of debt, housing insecurity, and reduced access to other essential services.
Insurance structures and disability benefit systems play a crucial role in shaping the economic burden. Because FND has historically been poorly understood and stigmatized, some patients encounter skepticism from insurers, disability assessors, or employers. Disputes over eligibility for benefits, return-to-work accommodations, or coverage for specific therapies can prolong financial uncertainty and add administrative costs. In some settings, lack of recognition of FND as a legitimate and disabling condition may lead to under-provision of necessary services, which paradoxically increases longer-term cost as untreated symptoms drive more crisis care.
At the population level, the aggregate cost of FND is magnified by its prevalence and by the intensity of resource use among those with severe or treatment-resistant forms. Even if per-patient costs vary widely, the combination of chronic disability, repeated acute care use, and long-term outpatient management yields a substantial cumulative economic impact. When compared with other neurological conditions, FND may command fewer targeted programs and less dedicated funding, yet it can consume a comparable or greater share of non-specific neurology, psychiatry, and emergency resources.
The broader societal impact extends beyond the formal healthcare system. Productivity losses due to absenteeism, presenteeism, and premature exit from the workforce represent a large, often undercounted, component of economic burden. Employers absorb the costs of reduced productivity, staff turnover, and accommodations, while social protection systems bear the costs of disability payments and vocational support. Family members may reduce their own work hours or leave employment to provide informal care, amplifying the indirect cost at the household and societal level.
Stigma and misunderstanding of FND contribute indirectly to its economic toll. When symptoms are minimized or dismissed as purely psychological or “not real,” people may delay seeking care or receive care that does not address their needs. Delayed or inappropriate management is not only clinically detrimental but also economically inefficient, as problems that might be mitigated earlier become more entrenched, requiring more intensive and costly interventions down the line. Addressing stigma, therefore, has both humanitarian and economic value, offering potential reductions in long-term cost through earlier, more effective intervention.
The economic burden is also shaped by geographic and socioeconomic inequities. Access to specialized FND services is often concentrated in urban tertiary centers, leaving rural or underserved populations reliant on local providers who may have limited expertise. Travel expenses, time away from work, and difficulty coordinating care across distances compound the financial impact for these patients. Moreover, individuals with lower income or less comprehensive insurance may face barriers to evidence-based therapies such as specialized physiotherapy or psychotherapy, resulting in a cycle where those with fewer resources experience worse outcomes and incur higher downstream costs.
From a health system perspective, understanding the full economic burden of FND is essential for rational planning and resource allocation. Without reliable cost and utilization data, FND remains invisible in many policy discussions, leading to underinvestment in services that might reduce overall expenditure. Efforts to quantify direct medical costs, indirect costs, and intangible effects such as reduced quality of life provide a foundation for evaluating the value of new models of care. This information can inform policy decisions about whether to invest in multidisciplinary clinics, training programs, and early-intervention pathways that could shift care from high-cost acute settings to more efficient, patient-centered services.
Ultimately, the economic burden of functional neurological disorder reflects a combination of clinical complexity, systemic gaps in care, and social determinants that influence access and outcomes. High rates of healthcare utilization, recurrent emergency visits and hospitalizations, long-term disability, and productivity loss interact to create a substantial and often underrecognized financial impact. Recognizing and accurately characterizing this burden is a prerequisite for meaningful change in service design, funding priorities, and clinical practice, and it lays the groundwork for evaluating future strategies aimed at both improving patient outcomes and reducing overall cost.
Direct medical costs and healthcare utilization
Direct medical costs associated with this condition are driven by a pattern of high and often inefficient healthcare utilization. Many individuals first come into contact with the system through urgent or unscheduled care, as sudden onset of weakness, movement symptoms, or seizure-like events is frequently interpreted as a possible stroke, epilepsy, or other acute neurological crisis. This leads to emergency visits that trigger rapid diagnostic pathways, including neuroimaging, laboratory studies, and consultation with neurology, all of which carry significant cost even when no structural pathology is ultimately identified.
Hospitalizations constitute one of the largest components of direct medical expenditure. People with recurrent seizure-like episodes, severe motor symptoms, or episodes of unresponsiveness may be admitted multiple times for observation and rule-out of life-threatening conditions. Inpatient stays typically involve serial neurologic examinations, continuous or repeated electroencephalogram monitoring, repeated imaging, and sometimes intensive care unit monitoring if there is concern for status epilepticus or respiratory compromise. Each admission aggregates bed-day costs, specialist fees, diagnostic tests, and ancillary services such as physical and occupational therapy assessments, which are magnified when diagnostic clarification is delayed.
Once admitted, clinical uncertainty can prolong the length of stay. When clinicians are unfamiliar with functional presentations or hesitant to make a positive diagnosis, additional rounds of testing may be ordered to search for rare organic causes. Even when results are repeatedly normal, the absence of a clear diagnostic framework can lead to further consultations—neurology, psychiatry, internal medicine, and sometimes cardiology or rheumatology. These overlapping evaluations add incremental cost without necessarily providing therapeutic benefit, illustrating how diagnostic hesitancy and lack of standardized pathways inflate direct medical spending.
Diagnostic imaging is a prominent contributor to cost in this context. Patients with motor symptoms or acute sensory changes frequently undergo multiple brain and spine magnetic resonance imaging scans over time, often combined with computed tomography to exclude acute hemorrhage or infarct during emergency presentations. Individuals with recurrent seizure-like episodes may have serial brain imaging, prolonged video-EEG monitoring, and additional tests to exclude inflammatory, metabolic, or genetic etiologies. While each investigation is clinically justified in early presentations, repetition of the same low-yield tests after an established diagnosis reflects an area where targeted education and guideline development could yield significant savings.
Across outpatient settings, the direct cost burden manifests as repeated specialist consultations and follow-up appointments. Many people see several neurologists before receiving a clear explanation, and some are also evaluated by epileptologists, movement disorder specialists, or neuromuscular clinics. When symptoms are accompanied by chronic pain, fatigue, or autonomic complaints, referrals may expand further to rheumatology, pain clinics, cardiology, or gastroenterology. Each referral generates new consultations, tests, and sometimes procedures, contributing to cumulative cost while fragmenting care.
Pharmacologic treatment patterns also influence direct medical costs. Before FND is recognized, patients with seizure-like episodes are often started on antiseizure medications, sometimes in combination at high doses, under the assumption of epilepsy. Others may receive long-term benzodiazepines, opioids, or muscle relaxants for pain and motor symptoms. These medications entail direct pharmacy costs and can lead to hospitalizations for adverse effects such as sedation, falls, or drug interactions. After an FND diagnosis is made, failure to deprescribe low-value medications prolongs unnecessary expenditure and may impede engagement with more effective non-pharmacologic therapies.
Primary care plays a dual role in shaping healthcare utilization and direct costs. On one hand, regular contact with a knowledgeable primary care provider can reduce unnecessary emergency visits by offering timely assessment, reassurance, and referral to appropriate services. On the other hand, when FND is poorly understood at the primary care level, repeated visits may lead to cascades of investigations or referrals initiated each time a new symptom arises. This cycle can be particularly costly in fee-for-service systems, where each visit and test generates additional charges without necessarily improving function or quality of life.
Mental health services represent an important but unevenly accessed component of direct medical costs. Psychotherapy, particularly approaches that integrate education about FND with cognitive-behavioral or psychodynamic techniques, can be highly valuable, yet access is often limited by workforce shortages, insurance coverage, or geographic barriers. In some systems, patients pay substantial out-of-pocket fees for psychological treatment, while in others, lack of funding for these services results in underuse of potentially cost-saving interventions. The imbalance between ready access to high-cost acute care and limited access to evidence-informed psychological and rehabilitative care represents a systemic misalignment of spending with clinical need.
Rehabilitation services—including physiotherapy, occupational therapy, and speech-language therapy—also carry direct costs that vary considerably depending on organization and funding. When these services are delivered within specialized FND programs that focus on retraining movement, attention, and symptom self-management, they may reduce long-term healthcare utilization by improving function and reducing crisis presentations. However, in settings where rehabilitation is not tailored to FND or is offered only intermittently, gains may be modest and patients may continue to rely heavily on hospital-based care. The cost profile therefore depends not only on the volume of rehabilitation but also on its quality, duration, and alignment with current understanding of FND mechanisms.
Another driver of direct costs is repeated presentation to diagnostic services after a diagnosis has been made but not fully accepted by either patient or clinician. For instance, a person with established functional seizures may continue to receive emergent neuroimaging, high-dose intravenous antiseizure medications, or even intubation and intensive care admission during acute episodes if frontline providers are unaware of the prior diagnosis or unprepared to manage it as FND. These scenarios are particularly expensive and highlight how gaps in communication, documentation, and clinical confidence translate directly into avoidable spending.
Variation in insurance coverage and payment models has a substantial impact on cost patterns. In systems where reimbursement favors procedures and acute care encounters over multidisciplinary outpatient management, hospitals and clinicians may be financially incentivized—consciously or not—to continue high-cost practices. Policies that do not reimburse for integrated FND clinics, telehealth follow-up, or collaborative case conferences inadvertently reinforce fragmented care and repeated emergency visits. Conversely, capitated or value-based payment models that reward reductions in hospitalizations and unnecessary testing can encourage the development of structured care pathways aimed at early diagnosis, coordinated treatment, and rational resource use.
Geographical disparities intersect with direct costs in complex ways. In regions without local specialist services, patients may be referred repeatedly to general neurology or psychiatry clinics with limited FND expertise, resulting in ongoing investigations without a coherent treatment plan. Travel to distant tertiary centers adds additional direct costs in the form of transportation, lodging, and time away from work, sometimes borne by health systems and sometimes by patients. Where specialized multidisciplinary clinics exist, they may demonstrate more efficient use of resources by concentrating expertise and reducing redundant testing, but their benefits are not equally distributed across populations.
Administrative and medicolegal processes can further inflate direct medical costs. Prolonged documentation for disability claims, workplace disputes, and, in rare cases, litigation may prompt additional assessments, independent medical examinations, and repeated imaging or laboratory testing aimed at “objectifying” symptoms. These activities seldom contribute meaningfully to clinical care, yet they consume clinician time and health system resources. Policy frameworks that promote early, collaborative communication between healthcare providers, insurers, and employers can reduce the reliance on costly, adversarial assessment pathways.
The structure of services and patterns of clinician decision-making determine whether direct medical spending on this condition produces commensurate clinical value. High rates of emergency visits and hospitalizations, repeated low-yield diagnostic testing, and prolonged use of ineffective medications all reflect system-level opportunities for cost reduction without compromising care. Realigning incentives toward early recognition, positive diagnosis, and access to evidence-informed multidisciplinary treatment has the potential to decrease unnecessary healthcare utilization while improving patient outcomes and reducing financial strain on individuals and health systems alike.
Indirect costs, productivity loss, and societal impact
Indirect costs associated with functional neurological disorder extend far beyond the formal healthcare budget and often eclipse direct medical spending. Lost productivity due to work disability, reduced work capacity, and premature retirement constitutes a central component of this burden. Many individuals with persistent symptoms find it difficult to maintain consistent employment, particularly in occupations that demand physical stamina, rapid responses, or sustained concentration. Even when complete withdrawal from the labor market does not occur, recurrent absences, reduced hours, and changes to less demanding and lower-paid roles collectively generate substantial income loss for patients and diminished output for employers.
Absenteeism is frequently the most visible dimension of productivity loss. People experiencing frequent functional seizures, episodic paralysis, or severe functional movement symptoms may be unable to attend work reliably, especially when symptoms are unpredictable or exacerbated by stress and fatigue. Repeated short-term sick leaves may eventually transition into long-term disability, and each stage carries its own economic consequences. Employers must arrange temporary coverage, redistribute work among colleagues, or recruit and train replacement staff, all of which increase operational cost and disrupt organizational continuity.
Presenteeism—being at work but functioning below one’s capacity—is an equally important yet less easily quantified driver of societal cost. Individuals with FND often contend with persistent fatigue, pain, cognitive fog, impaired concentration, and heightened anxiety about symptom recurrence. These factors can slow work pace, increase error rates, and limit the ability to take on new responsibilities or career advancement opportunities. From a macroeconomic perspective, large numbers of people working at reduced effectiveness translate into lower overall productivity and decreased return on investments in education and workforce development.
Vocational instability is common, with many people cycling through periods of employment, short-term contracts, and unemployment as symptoms fluctuate. Gaps in employment can erode skills and work confidence, making re-entry into the labor market progressively more difficult. For younger adults whose symptoms begin during critical years of education or early career formation, FND can interfere with completing degrees or apprenticeships, leading to long-term disadvantage in earnings and job prospects. This trajectory amplifies lifetime productivity loss, with cumulative effects that extend well beyond the immediate period of active symptoms.
Informal caregiving by family members or close friends constitutes another major category of indirect cost. Partners, parents, or adult children may reduce their own working hours, turn down promotions, or leave employment altogether to provide supervision, assist with activities of daily living, accompany the person to appointments, or respond to acute episodes. These caregiving demands are often unpredictable and can disrupt stable employment patterns, particularly in jobs with rigid schedules or limited flexibility. The opportunity cost of forgone earnings and career progression for caregivers is rarely captured in routine cost analyses yet represents a significant hidden transfer of economic burden from formal systems to households.
Caregiving also imposes psychosocial strain that can indirectly affect economic outcomes. Chronic stress, sleep disruption, and emotional burden increase the risk of mental and physical health problems among caregivers, potentially leading to their own increased healthcare utilization, absenteeism, or early retirement. Multigenerational effects are possible when caregiving responsibilities interfere with parenting, education, or employment opportunities for other family members, propagating disadvantage across time and affecting household resilience to economic shocks.
Social protection systems absorb large portions of the indirect costs through disability benefits, income support, housing assistance, and vocational rehabilitation programs. Many individuals with FND apply for partial or full disability benefits when work becomes unsustainable. The process of establishing eligibility often requires extensive documentation, repeated assessments, and, in some cases, appeals or legal representation, all of which entail administrative expense. Delays or disputes regarding benefits can exacerbate financial instability, increase stress, and may worsen symptoms, indirectly perpetuating healthcare utilization and further disability.
The design of disability and welfare policies strongly shapes both the scale and distribution of these indirect costs. Systems that require strong emphasis on structural pathology or overtly objective findings can disadvantage people with FND, despite substantial functional impairment. This mismatch may lead to denial of benefits for some and prolonged adversarial processes for others, generating additional legal and administrative cost without corresponding societal value. Conversely, overly permissive systems that provide income support without adequate access to evidence-informed treatment and vocational support may inadvertently reinforce long-term disengagement from the workforce, locking in high productivity losses.
Educational disruption is a critical but underrecognized dimension, particularly for adolescents and young adults. Recurrent emergency visits, hospitalizations, and ongoing symptoms can cause missed school days, reduced participation, and difficulties completing examinations. Stigma and misunderstanding within educational settings can compound these problems, leading to withdrawal from school or reduced academic attainment. The long-term economic implications include limited access to higher education, constrained career choices, and decreased lifetime earnings, which accumulate into substantial societal cost when considered across a population.
Transportation and logistical challenges add another layer of indirect burden. People with frequent functional seizures may be restricted from driving, at least temporarily, depriving them of independent mobility and affecting their ability to commute to work, school, or healthcare appointments. Reliance on public transportation, rides from relatives, or paid transport services introduces additional expenditures and time costs. In rural or poorly served areas, these constraints can effectively exclude individuals from employment or educational opportunities that require reliable and flexible travel, exacerbating social and economic isolation.
Stigma and misunderstanding surrounding FND have pervasive socioeconomic consequences. When symptoms are misinterpreted as feigned, exaggerated, or purely psychological, individuals may encounter skepticism from employers, colleagues, educators, and even family members. Such attitudes can hinder reasonable workplace accommodations, prompt discriminatory treatment, or contribute to job loss. Fear of not being believed may lead some to conceal symptoms or avoid seeking accommodations, thereby increasing the risk of safety incidents, performance problems, or crisis presentations that carry greater cost for both individuals and organizations.
At the community level, stigmatization undermines social capital and support networks that buffer against financial hardship. People who feel judged or misunderstood may withdraw from social activities, community groups, or peer networks that could otherwise provide informal assistance, job leads, or emotional support. Diminished social connectedness increases vulnerability to poverty, housing insecurity, and marginalization, which in turn are associated with higher rates of mental health difficulties and healthcare use. These interlocking factors create feedback loops in which social disadvantage and illness mutually reinforce each other, deepening the long-term societal impact.
Housing instability and poverty are both contributors to, and consequences of, the economic burden of this condition. Lost income, increased caregiving responsibilities, and out-of-pocket expenses for treatment or travel can erode savings and push households toward rent arrears, eviction risk, or overcrowded living arrangements. Insecure or inadequate housing can exacerbate symptoms by increasing stress, limiting privacy, and restricting opportunities for rest and self-management, thereby driving further episodes, absences from work, and interactions with emergency and social services. These complex interactions underscore that the societal cost of FND cannot be understood in isolation from broader social determinants of health.
Justice and legal systems sometimes become involved, adding further indirect costs. Episodes that resemble seizures, fainting, or disruptive behavior may lead to emergency service callouts, law enforcement involvement, or legal disputes, particularly when misunderstandings occur in public settings or workplaces. In addition, contested insurance claims, workplace termination cases, and disability appeals may require legal representation, court time, and independent medical examinations. While these processes seek to resolve rights and responsibilities, they absorb public and private resources and can prolong uncertainty and stress for the individuals concerned.
Another indirect dimension involves the opportunity costs of underutilized human potential. Many people with FND possess high levels of education, training, and experience but are prevented from applying these capacities fully due to fluctuating symptoms, lack of accommodations, or absence of structured return-to-work support. From a societal standpoint, investments in education and professional development yield lower returns when individuals are pushed to the margins of the labor market. This underemployment represents a silent but significant erosion of economic value that standard cost calculations often fail to capture.
Workplace accommodations and flexible employment policies can mitigate some of these losses when implemented effectively. Adjustments such as flexible scheduling, remote work options, modified duties, access to rest breaks, and clear crisis response plans may enable continued participation in the workforce for many individuals with FND. However, lack of awareness among employers, concerns about liability, and uncertainty regarding prognosis often result in missed opportunities for collaborative solutions. Where supportive policies and occupational health services are absent or underused, early and potentially preventable exits from employment become more common, magnifying long-term productivity loss.
Vocational rehabilitation and supported employment programs have the potential to reduce indirect costs by facilitating gradual return to work, retraining for more suitable roles, and negotiation of workplace adjustments. When such services are grounded in a modern understanding of FND and coordinated with clinical care, they can help individuals rebuild confidence, skills, and routines, thereby enhancing long-term economic participation. In contrast, generic or poorly informed vocational services may unintentionally reinforce avoidance of activity, fail to address specific symptom patterns, or set unrealistic expectations, limiting their effectiveness in restoring productivity.
Educational and workplace interventions that target stigma and promote accurate understanding of FND can generate substantial societal value. Training for teachers, managers, and human resources professionals on recognition, reasonable adjustments, and support strategies may prevent school dropout and job loss, preserving human capital and reducing reliance on disability benefits. Such interventions, while modest in direct cost, can influence trajectories across decades by keeping individuals engaged in education and employment pathways that would otherwise be disrupted.
Societal impact also arises from the interplay between FND and other chronic conditions. Comorbid pain syndromes, mood disorders, and autonomic dysfunction are frequent, and their presence increases the complexity of care needs and the likelihood of prolonged functional impairment. These overlapping conditions can intensify disability, further reduce productivity, and require additional informal caregiving. When health and social systems address each condition in isolation rather than through integrated pathways, duplication of services and fragmented support may amplify indirect costs while failing to optimize outcomes.
From a policy perspective, accurately capturing and valuing indirect costs is essential for informed resource allocation. Economic evaluations that focus solely on direct medical expenditures risk underestimating the true burden and, consequently, undervaluing interventions that primarily affect work participation, caregiving demands, or educational attainment. Incorporating measures of productivity loss, caregiver time, and social welfare utilization into cost-of-illness studies and cost-effectiveness analyses provides a more comprehensive picture of the societal impact. This broader lens helps justify investment in early diagnosis, multidisciplinary rehabilitation, vocational support, and anti-stigma initiatives that may appear relatively expensive from a narrow healthcare budget perspective but yield net societal gains.
Methodological challenges remain in quantifying these indirect and societal costs, including variability in employment patterns, informal caregiving arrangements, and welfare structures across countries and regions. Nonetheless, emerging evidence suggests that productivity losses and social welfare expenditures represent a substantial share of the overall economic burden. Efforts to standardize outcome measures related to work status, caregiving time, and social participation in clinical and health services research will enhance the accuracy of future estimates and strengthen the basis for policy decisions. As these data accumulate, they can inform targeted strategies to reduce not only the visible clinical impact of FND but also the extensive, often hidden, societal costs that currently accompany it.
Cost-effectiveness of diagnostic and treatment strategies
Evaluating the cost-effectiveness of diagnostic and treatment strategies for functional neurological disorder requires careful consideration of both clinical outcomes and patterns of healthcare utilization. Traditional pathways dominated by repeated emergency visits, extensive investigations, and fragmented follow-up tend to be expensive while offering modest long-term benefits. In contrast, approaches that prioritize early, positive diagnosis and coordinated multidisciplinary treatment demonstrate growing evidence of better outcomes at lower or comparable overall cost, particularly when indirect costs and quality-of-life gains are considered.
One of the clearest examples of cost-effective intervention is early access to specialist assessment that enables a confident, positive diagnosis. Prolonged diagnostic uncertainty fuels repeated hospitalizations, duplicate imaging, and ongoing pharmacologic trials with limited benefit. Studies of structured diagnostic pathways—such as rapid-access clinics for seizure-like episodes or movement symptoms—indicate that timely recognition of functional presentations can substantially reduce subsequent acute care use. By minimizing unnecessary tests and preventing years of misdirected treatment, these pathways generate savings that often exceed the upfront investment in specialist time and diagnostic infrastructure.
Video-EEG monitoring for suspected seizures illustrates how a relatively high-cost diagnostic tool can be highly cost-effective when applied appropriately. While prolonged monitoring is expensive on a per-patient basis, early and accurate identification of functional seizures can lead to discontinuation of ineffective antiseizure medications, reduction in intensive care admissions for pseudo–status epilepticus, and fewer emergency calls and ambulance transports. When the downstream reductions in resource use are quantified, the net cost of early video-EEG diagnosis is often lower than the cumulative expenditure associated with years of mismanaged presumed epilepsy.
Similarly, specialist neurological assessment that includes bedside examination techniques tailored to detect internal inconsistency and positive functional signs can provide a diagnosis without extensive additional testing. Training programs that enhance clinicians’ skills in recognizing these signs may require modest educational investment but can shift practice away from repetitive low-yield investigations. Economic models suggest that even small reductions in high-cost imaging and inpatient stays can produce favorable cost-effectiveness ratios when multiplied across the population of patients presenting with unexplained neurological symptoms.
Multidisciplinary FND clinics offer a more comprehensive example of cost-effective care. These services typically bring together neurologists, psychiatrists or psychologists, and physiotherapists or occupational therapists to deliver integrated assessment and treatment. Although the per-episode cost of multidisciplinary intervention may exceed that of a single specialist visit, outcome studies consistently show improvements in symptom severity, functional independence, and quality of life. When reductions in future emergency visits, unplanned hospitalizations, and repeated diagnostic workups are factored in, the overall cost trajectory often bends downward. Cost-utility analyses that incorporate quality-adjusted life years (QALYs) have begun to show that these clinics deliver good value for money compared with usual care, particularly for patients with severe or chronic symptoms.
Rehabilitation-based interventions specifically designed for functional motor symptoms have also demonstrated promising cost-effectiveness profiles. Intensive, time-limited physiotherapy programs that emphasize movement retraining, attentional refocusing, and graded activity often produce durable gains in mobility and self-care. These gains translate into reduced dependence on caregivers, lower rates of long-term disability benefits, and fewer encounters with acute care services. When evaluated over a multi-year horizon, the initial cost of specialized rehabilitation is frequently offset by decreased healthcare utilization and increased work participation, yielding favorable incremental cost-effectiveness ratios compared with non-specialist or purely biomedical management.
Psychological therapies tailored to FND, including cognitive-behavioral approaches and psychodynamic or integrative models, represent another area where cost-effectiveness is increasingly documented. Structured interventions that combine psychoeducation about FND mechanisms with strategies for managing triggers, catastrophic thinking, and avoidance behaviors can reduce symptom frequency and functional impairment. Randomized and observational studies suggest that, although such therapies require trained clinicians and multiple sessions, they can substantially lower subsequent medical costs by decreasing crisis presentations and fostering self-management. When improvements in mental health and role functioning are included in economic evaluations, these therapies often fall within or below commonly accepted willingness-to-pay thresholds per QALY gained.
Digital and telehealth adaptations of these treatments hold particular promise for enhancing cost-effectiveness at scale. Internet-delivered psychotherapy modules, tele-rehabilitation, and remote group education sessions can extend specialist expertise to geographically dispersed populations without requiring extensive travel or long in-person appointments. While the evidence base is still emerging, preliminary analyses suggest that digital interventions can deliver clinically meaningful benefits at lower marginal cost, especially when integrated with brief in-person assessments. From a system perspective, such hybrid models may optimize the balance between access, intensity of support, and budget impact.
Educational interventions focused on clinicians are comparatively low-cost yet can generate substantial savings by changing practice patterns. Training emergency, neurology, and primary care teams to recognize FND, communicate the diagnosis effectively, and implement basic management plans can decrease reliance on high-cost investigations and unplanned admissions. Simulation-based education, online modules, and decision-support tools embedded in electronic health records entail modest development and maintenance costs, but their potential to reduce repeated imaging, avoid inappropriate intensive care admissions, and streamline referral pathways positions them as highly cost-effective system-level strategies.
Cost-effectiveness analyses also highlight the importance of deprescribing and rational pharmacotherapy. Discontinuation of unnecessary antiseizure medications, opioids, benzodiazepines, and other symptomatic drugs after a confirmed FND diagnosis reduces direct pharmacy costs and lowers the risk of medication-related complications requiring medical attention. Systematic medication review protocols embedded in FND clinics or primary care follow-up can be implemented at relatively low cost, while the downstream savings from fewer adverse events, falls, and drug interactions can be considerable. When combined with active rehabilitation and psychological treatment, rational pharmacologic management becomes a core component of value-based care.
Another dimension of cost-effectiveness concerns the timing of intervention. Evidence increasingly suggests that earlier engagement with appropriate treatment yields better outcomes than delayed referral after years of chronic symptoms. Early intervention can prevent the consolidation of disability, reduce secondary psychiatric comorbidities, and maintain ties to the workforce or education. From an economic standpoint, interventions delivered during the initial months of illness may avert the high long-term costs associated with entrenched disability, prolonged unemployment, and recurrent crisis care. Economic models that extend the time horizon to capture these long-term savings often show more favorable cost-effectiveness ratios for early, proactive treatment strategies compared with reactive, late-stage approaches.
However, demonstrating cost-effectiveness in this field is complicated by methodological challenges. Variability in diagnostic criteria, outcome measures, and follow-up duration across studies limits direct comparison of interventions. Many evaluations rely on small sample sizes or single-center designs, constraining generalizability. Furthermore, some analyses focus narrowly on direct healthcare costs and overlook indirect economic effects such as productivity gains or reduced reliance on social welfare. When broader societal costs are included—such as caregiver burden, lost earnings, and educational disruption—the relative value of effective diagnostic and treatment strategies becomes even clearer, but collecting and modeling these data requires additional resources and methodological expertise.
Despite these challenges, emerging economic evidence points toward several consistent themes. Strategies that reduce diagnostic delay and avoid repetitive, low-yield testing tend to be cost-saving or highly cost-effective. Multidisciplinary, biopsychosocially informed interventions outperform fragmented usual care in both clinical and economic terms for many patients. Interventions that support return to work, maintain educational engagement, or reduce caregiver dependence generate substantial societal value even when their direct costs appear high from a narrow healthcare budget perspective. These findings provide a growing empirical foundation for reorienting services away from crisis-driven, investigation-heavy care and toward coordinated, evidence-informed treatment pathways.
In designing and assessing new interventions, it is essential to consider heterogeneity among patients. Some individuals may benefit from brief education and reassurance with minimal ongoing input, while others with complex comorbidities or longstanding disability may require more intensive and costly multidisciplinary programs. Tailoring the intensity of intervention to clinical need can optimize cost-effectiveness by avoiding both under-treatment in complex cases and over-treatment in milder presentations. Stratified care models that use early assessment to assign patients to different levels of intervention, combined with stepped-care approaches that escalate treatment only when necessary, offer a promising framework for aligning resource use with expected benefit.
Equity considerations are also integral to discussions of cost-effectiveness. Interventions that are cost-effective on average may still be underutilized by rural, low-income, or minority populations due to access barriers. Analyses that ignore these disparities risk endorsing strategies that inadvertently widen health gaps. Incorporating equity weights, subgroup analyses, or distributional cost-effectiveness methods can help ensure that resource allocation decisions reflect not only aggregate efficiency but also fairness. In the context of this condition, policies that expand access to telehealth, subsidize travel for specialist care, or support translation and culturally adapted treatments may improve both equity and overall value by reducing reliance on high-cost emergency and inpatient care in underserved groups.
Ultimately, the cost-effectiveness of diagnostic and therapeutic strategies in this area hinges on how well they realign care with the known mechanisms and trajectories of the disorder. Interventions that acknowledge the functional nature of symptoms, provide clear and validating explanations, and engage patients in active rehabilitation consistently outperform those that continue to pursue elusive structural explanations or rely solely on pharmacologic symptom suppression. As economic evaluations become more sophisticated—incorporating long-term outcomes, societal costs, and patient-reported measures of function and participation—they are increasingly converging on the conclusion that shifting investment toward early diagnosis, multidisciplinary treatment, and clinician and public education represents not only a clinically sound approach but also a prudent use of limited healthcare resources.
Policy implications and resource allocation for fnd
Policy responses to functional neurological disorder must reconcile substantial unmet clinical needs with finite resources and competing priorities. Because the condition has historically been under-recognized in planning processes, it often falls between neurology, psychiatry, rehabilitation, and mental health budgets, with no single entity accountable for outcomes or expenditure. A central implication for policymakers is the need to explicitly acknowledge this diagnostic group within health strategies, data systems, and commissioning frameworks so that costs, healthcare utilization, and outcomes can be monitored and optimized rather than remaining invisible and fragmented.
Incorporating this condition into national and regional health plans begins with better use of routine data. Coding systems, electronic health records, and hospital episode statistics frequently misclassify or fail to capture functional presentations, leading to underestimation of prevalence and cost. Updating diagnostic coding guidance, creating specific reporting categories, and training clinicians and coders to use them consistently would enable more accurate tracking of emergency visits, hospitalizations, and outpatient episodes. These data, in turn, provide the evidence base needed to justify investment in specialized services and to evaluate the impact of policy changes on both expenditures and patient outcomes.
Resource allocation decisions should prioritize development of structured care pathways that span acute, outpatient, and community settings. Unplanned care is expensive and often ineffective when relied upon as the primary management strategy. Policymakers can incentivize the establishment of rapid-access neurology clinics for new-onset seizure-like events or motor symptoms, with explicit protocols for identifying functional signs and initiating early explanation and treatment. Funding models that support these front-end services, while rewarding reductions in avoidable admissions and repetitive diagnostic testing, align financial incentives with clinical value rather than volume.
Commissioning multidisciplinary clinics dedicated to this condition is a pivotal policy lever. Such services bring together neurologists, psychiatrists or psychologists, and rehabilitation professionals in a single, coordinated team. Although they require upfront investment in staffing and infrastructure, evidence suggests that they reduce high-cost utilization over time by curbing repeated emergency visits, prolonged diagnostic workups, and crisis-driven hospitalizations. Policymakers can support these models by ring-fencing budget lines, setting performance indicators linked to outcomes and healthcare utilization, and ensuring that referral criteria and pathways are clearly communicated across primary and secondary care.
Payment reform is fundamental to realigning incentives. Fee-for-service environments may inadvertently encourage repeated investigations and specialist consultations, while offering little support for time-intensive communication, psychoeducation, and coordination that add substantial value for these patients. Policy options include bundled payments for defined episodes of care, capitated contracts that reward lower downstream cost and better outcomes, or value-based purchasing schemes in which providers receive bonuses for reducing unnecessary admissions, imaging, and low-yield pharmacotherapy. Embedding explicit quality and outcome metrics related to functional presentations into these payment models ensures that cost savings do not come at the expense of patient-centered care.
Workforce development is another critical area for policy intervention. Many clinicians receive minimal formal training on this condition during undergraduate or specialty education, contributing to diagnostic delays, uncertainty, and sometimes stigmatizing responses that undermine engagement. Policymakers, professional bodies, and academic institutions can mandate inclusion of relevant content in neurology, psychiatry, primary care, emergency medicine, and rehabilitation curricula. Funding protected time for continuing professional development, simulation-based training, and interdisciplinary case conferences can build confidence in making a positive diagnosis and implementing evidence-informed management, which in turn reduces reliance on costly, repetitive investigations.
To ensure efficient use of resources, policies should promote stepped and stratified care models. Not every patient requires intensive multidisciplinary intervention; some may benefit sufficiently from early explanation, brief psychological therapy, or targeted physiotherapy. Designing tiered service structures—ranging from self-help and primary care–based interventions to highly specialized multidisciplinary programs for complex or refractory cases—allows allocation of more expensive resources to those with the greatest expected benefit. Commissioning frameworks can embed criteria for step-up and step-down care, linked to standardized outcome measures, to avoid both over-treatment and under-treatment.
Telehealth and digital tools offer policy-enabled opportunities to extend specialized expertise without the high marginal cost of frequent in-person visits. Regulations and reimbursement policies that recognize remote consultations, group education sessions, and digital rehabilitation or psychotherapy programs as reimbursable services can markedly improve access, particularly for rural or underserved populations. Policymakers can support pilot programs and evaluations of hybrid care models that combine brief in-person assessments with ongoing remote follow-up, assessing their impact on hospitalizations, emergency visits, and longer-term disability costs.
Integration across sectors is essential, as many of the most significant economic impacts occur outside the healthcare budget. Disability benefits, vocational rehabilitation, education services, and social care all bear substantial costs when people experience prolonged functional impairment. Cross-sector policy frameworks—such as shared outcome targets, joint commissioning arrangements, or pooled budgets—can encourage coordinated approaches that emphasize early intervention and return to participation in work and education. For example, co-funded multidisciplinary programs involving health and employment services can support graduated return to work, thereby reducing long-term dependence on income support and maximizing the value of public investment.
Disability assessment and social protection policies warrant specific attention. Systems that rely heavily on structural findings to verify disability can disadvantage individuals with severe functional symptoms, resulting in protracted appeals, adversarial assessments, and duplication of costly independent evaluations. Policymakers can revise eligibility criteria and guidance to explicitly recognize this condition as potentially disabling, while coupling income support with access to evidence-based treatment and vocational support. This approach balances fairness with incentives for recovery, reducing administrative overhead and aligning social expenditures with interventions that improve function rather than entrenching long-term inactivity.
Workplace regulation and occupational health policy also shape outcomes and costs. Legislative frameworks that mandate reasonable accommodations for health-related limitations can protect employment for people with persistent symptoms. Policy guidance for employers and occupational health providers can outline practical adjustments—such as flexible scheduling, remote work, modified duties, and crisis management plans—that help maintain productivity and reduce turnover. Governments can partner with employer organizations and unions to develop toolkits and training programs that demystify this condition and reduce stigma, recognizing that sustained employment is both clinically beneficial and cost-saving for social protection systems.
Educational policy plays a similar role for children and young adults. Absenteeism, school avoidance, and early dropout carry long-term economic consequences, yet many schools lack guidance on supporting affected students. Education authorities can issue policy directives and resource materials to help schools implement individualized learning plans, graded attendance, and coordinated communication with healthcare providers. Investment in school-based mental health and special education support for these students may appear modest compared with the future costs of unemployment, social exclusion, and high healthcare utilization, making it a high-value policy choice over the life course.
Equity considerations must be integrated into all policy and resource allocation decisions. Populations in rural areas, low-income communities, or minority groups often face greater barriers to accessing specialized services, which can lead to higher rates of unplanned care and poorer long-term outcomes. Policymakers can direct targeted funding to expand outreach clinics, teleconsultation networks, interpreter services, and culturally adapted interventions. Incorporating equity metrics into performance dashboards—such as disparities in waiting times, admission rates, or treatment completion—helps ensure that the benefits of improved pathways and reduced cost are shared across all segments of the population.
Research and evaluation infrastructure should be a core component of the policy response. Dedicated funding streams for health services research, clinical trials, and implementation studies are needed to refine diagnostic criteria, treatment models, and service configurations. Policymakers can encourage inclusion of economic endpoints—such as changes in healthcare utilization, employment status, and social welfare dependence—in research protocols to generate robust evidence for cost-effectiveness analyses. Establishing registries and longitudinal cohorts facilitates ongoing assessment of how policy changes influence trajectories over time, allowing iterative refinement of resource allocation decisions.
Public and patient engagement is another important dimension of policy design. People with lived experience offer insights into barriers, facilitators, and unintended consequences of service changes that may not be visible from administrative data. Formal mechanisms—such as advisory panels, co-production of clinical pathways, and patient-reported outcome and experience measures embedded in routine care—ensure that policies are grounded in real-world needs and priorities. Engaged patients are more likely to participate in rehabilitation, adhere to treatment plans, and help design services that are acceptable and efficient, thereby enhancing both clinical and economic value.
Stigma reduction campaigns, supported at the policy level, can contribute indirectly but meaningfully to improved outcomes and more efficient use of resources. Public awareness initiatives that explain the nature of this condition, emphasize that symptoms are real and potentially reversible, and highlight effective treatments can reduce shame, delay in help-seeking, and confrontational interactions with services. Partnering with advocacy groups, professional societies, and media organizations allows policymakers to amplify accurate messages and counter misinformation, which in turn supports earlier diagnosis, better engagement with care, and lower reliance on crisis services.
Policy frameworks must remain adaptable as the evidence base evolves. As new treatments, service models, and digital tools emerge, regular review of guidelines, commissioning specifications, and reimbursement rules is necessary to ensure that resources continue to be allocated to the highest-value options. Establishing national or regional steering committees that bring together clinicians, researchers, service planners, payers, and patient representatives can support continuous learning and coordinated response. In this way, policy and resource allocation decisions can progressively move the system from reactive, high-cost management toward proactive, integrated, and economically sustainable care that better reflects the true burden and potential for recovery associated with this condition.
